PTN
Latest Trade
0.46USDChange
-0.01(-1.25%)Volume
389,575Today's Range
-
0.4752 Week Range
-
1.30As of on the Nyse American LLC ∙ Minimum 15 minute delay
Previous Close | 0.46 |
|---|---|
Open | 0.45 |
Volume | 389,575 |
3M AVG Volume | 25.76 |
Today's High | 0.47 |
Today's Low | 0.45 |
52 Week High | 1.30 |
52 Week Low | 0.38 |
Shares Out (MIL) | 230.12 |
Market Cap (MIL) | 106.41 |
Forward P/E | -4.03 |
Dividend (Yield %) | -- |
Palatin Announces Positive End-Of-Phase 2 Meeting With FDA On Pl9643 For The Treatment Of Dry Eye Disease
Palatin Reports Q3 Loss Per Share Of $0.02
Palatin Technologies Reports Q2 Fiscal Year 2021 Financial Results And Recent Business Highlights
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.
Industry
Biotechnology & Drugs
Contact Info
4B Cedar Brook Drive
CRANBURY, NJ
08512
United States
+1.609.4952200
https://www.palatin.com/Executive Leadership
John K. A. Prendergast
Independent Chairman of the Board
Carl Spana
President, Chief Executive Officer, Director
Stephen T. Wills
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
Robert K. deVeer
Independent Director
Alan William Dunton
Independent Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 1.69 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -34.23 |
Return on Equity (TTM) | -31.55 |
* PALATIN TECHNOLOGIES, INC. ANNOUNCES REINITIATION OF ENROLLMENT OF PHASE 2 STUDY WITH PL9643 FOR THE TREATMENT OF DRY EYE DISEASE
* PALATIN TECHNOLOGIES TO DEVELOP PL8177 AS A POTENTIAL TREATMENT FOR COVID-19 AND ASSOCIATED LUNG COMPLICATIONS
* PALATIN TECHNOLOGIES, INC. REPORTS THIRD QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
* PALATIN TECHNOLOGIES INC - CASH AND CASH EQUIVALENTS OF $88.9 MILLION AS OF MARCH 31, 2020
* PALATIN TECHNOLOGIES, INC. ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2 CLINICAL TRIAL WITH PL9643
* PALATIN TECHNOLOGIES, INC. REPORTS SECOND QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals' drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as "female Viagra".
The U.S. Food and Drug Administration on Friday approved Palatin Technologies Inc and Amag Pharmaceuticals Inc's drug to restore sexual desire in premenopausal women, Amag said.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.